Authors
- Sisca Silvana, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia AND Department of Pediatrics, Faculty of Medicine, Universitas HKBP Nommensen, Medan, Indonesia.Follow
- Iskandar Japardi, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, IndonesiaFollow
- Muhammad Rusda, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
- Rini Savitri Daulay, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
- Agung Putra, Stem Cell and Cancer Research (SCCR), Faculty of Medicine, Universitas Islam Sultan Agung (Unissula), Semarang, Indonesia.Follow
- Irawan Mangunatmadja, Department of Pediatrics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.Follow
- Dewi Masyithah Darlan, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
- Sri Sofyani, Philosophy Doctor in Medicine Program, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.Follow
- Yana Andreas, Faculty of Medicine, Universitas HKBP Nommensen, Medan, Indonesia.Follow
Abstract
Standard treatments for ischemic stroke are intravenous thrombolysis and endovascular recanalization. In the acute phase (
Keywords
CD31, VEGF, Secretome, MSC, Ischemic Stroke
How to Cite this Article
Silvana, Sisca; Japardi, Iskandar; Rusda, Muhammad; Daulay, Rini Savitri; Putra, Agung; Mangunatmadja, Irawan; Darlan, Dewi Masyithah; Sofyani, Sri; and Andreas, Yana
(2025)
"Mesenchymal Stem Cell Secretome for Ischemic Stroke: CD31 and VEGF Expression,"
Baghdad Science Journal: Vol. 22:
Iss.
4, Article 14.
DOI: https://doi.org/10.21123/bsj.2024.11813
DOWNLOADS
Since April 22, 2025
COinS